e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Innovations in the assessment of airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum hyaluronate: A new biomarker of passive smoking-induced lung injury in asthmatic patients
R. Mohamed, A. Khafagy, A. E. Saad, N. Abdelaty, N. Moustafa (Ismailia, Egypt)
Source:
Annual Congress 2010 - Innovations in the assessment of airway diseases
Session:
Innovations in the assessment of airway diseases
Session type:
Thematic Poster Session
Number:
4608
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Mohamed, A. Khafagy, A. E. Saad, N. Abdelaty, N. Moustafa (Ismailia, Egypt). Serum hyaluronate: A new biomarker of passive smoking-induced lung injury in asthmatic patients. Eur Respir J 2010; 36: Suppl. 54, 4608
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Lung and serum biomarkers of tissue lesions due to acute exacerbation of COPD
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019
Serum periostin is not a good biomarker to identify Th2-driven inflammation in COPD
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Markers of pulmonary injury and inflammation are elevated in the serum of patients with chronic cough
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Year: 2021
Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema
Source: Eur Respir J 2001; 18: Suppl. 33, 248s
Year: 2001
Effect of one moderate or mild exacerbation on lung function and serum inflammatory markers in ex smokers patients with COPD
Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients
Year: 2009
Increased serum endotoxin levels as biomarker in acute exacerbations of COPD.
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Inflammation biomarkers of lung tissue damage in acute exacerbation of COPD patients
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Usefulness of a panel of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021
Plasma markers of oxidative protein damage do not correlate with lung function or COPD in smokers
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006
Serum heat shock protein 47 levels in patients with drug induced lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Role of systemic and bronchial oxidative stress and inflammation in lung cancer predisposition in patients with COPD
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Serum eosinophil cationic protein as a marker of disease severity in patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 51s
Year: 2001
Relationships between lung physiology and airway and systemic inflammation: a cohort study in COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006
Is lung emphysema in COPD patients reflected by central airways inflammation?
Source: Eur Respir J 2003; 22: Suppl. 45, 207s
Year: 2003
Total desmosines in plasma and urine correlate with lung function
Source: Eur Respir J 2012; 39: 839-845
Year: 2012
Airway obstruction and or emphysema shows a different plasma inflammatory response in asymptomatic smokers or ex-smokers participating in a lung cancer screening program
Source: Annual Congress 2010 - Lung morbidity on exposure to various agents
Year: 2010
Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept